How are businesses across the health care and life sciences spectrum collaborating to capitalize on the commercial promise of personalized medicine? Join us at the Business of Personalized Medicine Summit at Oyster Point on Thursday, February 27, 2020, to find out!
Since the completion of the Human Genome Project in 2003, the genomic revolution has spurred immeasurable excitement and support surrounding the promise of personalized medicine, setting high expectations for a new era of health care and rapidly transforming the field into a multi-billion dollar industry.
While realizing the medical and commercial potential of personalized medicine has turned out to be neither quick nor easy, we could finally be on the cusp of widespread clinical adoption and improved patient outcomes thanks to recent scientific and technological advances, including with CRISPR gene editing and targeted therapies. In fact, in its latest report, Cancer Statistics, 2020, the American Cancer Society cites a 2.2% drop in the U.S. cancer death rate from 2016 to 2017 — the largest single-year drop ever recorded — and attributes it largely to the development of targeted therapies and other personalized medicines for the treatment of lung and skin cancers.
With this welcome news underscoring the real medical contributions of personalized medicine, this year’s Summit aims to explore whether the business community might also be on the verge of capitalizing on the field’s commercial promise and, if so, what that could mean for innovation, investment, profitability, and growth in the space moving forward. You won’t want to miss these one-of-a-kind discussions with key industry executives in the birthplace of biotechnology — RSVP to attend today.
Registration is complimentary for life sciences and health care executives, entrepreneurs, investors, and academics. For more information, visit www.personalizedmedicinesummit.com or contact Allison Jones at [email protected].
Featured Discussion Topics
|The capital raising landscape and lessons learned|
|Spotlight on gene and cell therapy as an innovative and evolving technology area|
|Capitalizing on the commercial potential of direct-to-consumer genetic testing|
|Strategies for operationalizing a personalized medicine program at the point of care|
|The promise behind AI for discovery, validation, diagnosis, and data sharing|
|Evolving business models for companion diagnostics|
Kathleen Barnes, PhD
Professor and Head, Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus
Paul Billings, MD, PhD
Anita Chawla, PhD
Nicholas Dracopoli, PhD
Ron Mazumder, PhD, MBA
Nick Naclerio, PhD
Ekta Patel, PhD
Kathryn Phillips, PhD
Professor of Health Services Research and Health Economics, Department of Clinical Pharmacy, UCSF School of Pharmacy
Bruce Quinn, MD, PhD
Interested in sponsoring the Business of Personalized Medicine Summit? Opportunities to support the 2020 program are still available. For more information, please contact Allison Jones at [email protected].
About the BPM Summit
What Makes the BPM Summit Unique?
Many forums for discussing personalized medicine focus on specialized areas such as underlying technologies, financing, regulatory pathways, or payment issues. The BPM Summit attempts to address cross-sections of such issues with a clear eye towards modeling successful and sustainable business models for entities already engaged in personalized medicine as well as those that seek to enter the space. The BPM Summit aims to set itself apart from other programs by focusing on the business challenges, trends, and opportunities within the personalized medicine marketplace while keeping in mind the potential implications for R&D and healthcare delivery.
Who Should Attend?
Business, legal, and health care professionals interested in industry leaders’ real-world experience on the current state of personalized medicine and where growth and opportunity exist
Business, legal, and health care professionals interested in discussions regarding the regulatory framework for diagnostics and targeted therapies
Executives and entrepreneurs interested in hearing diverse perspectives on both the development and delivery of personalized medicine therapies
Payers interested in the current status and future possibilities regarding reimbursement of personalized medicine technologies
Corporate counsel in life sciences and health care provider organizations
Health care professionals working in the field of personalized medicine
Health care and life sciences investors
Researchers and academic personnel